Another study reported that recombinant human EPO administration significantly improved the attention/memory domain score of the Non-Motor Symptoms Scale for Parkinson’s disease (p < 0.01) and the cognitive domain score of the 39-item Parkinson’s Disease Questionnaire (p < 0.01) at 12 months in 26 patients with Parkinson’s disease (106). This evidence concerns the gene EPO and Parkinson disease.